Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

8.3%

1 terminated/withdrawn out of 12 trials

Success Rate

90.0%

+3.5% vs industry average

Late-Stage Pipeline

75%

9 trials in Phase 3/4

Results Transparency

89%

8 of 9 completed trials have results

Key Signals

1 recruiting8 with results

Enrollment Performance

Analytics

Phase 3

7(58.3%)

Phase 4

2(16.7%)

N/A

2(16.7%)

Phase 1

1(8.3%)

12Total

Phase 3(7)

Phase 4(2)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (12)

Showing 12 of 12 trials

NCT06658002Phase 3Recruiting

Fungal Ulcer Treatment Augmented With Natamycin and Cyclosporine A

Role: collaborator

NCT02731638Phase 3Completed

Mycotic Antimicrobial Localized Injection for Treatment of Corneal Ulcers

Role: collaborator

NCT02570321Phase 3Completed

Cross-linking for Corneal Ulcers Treatment Trial

Role: collaborator

NCT01829295Phase 3Completed

Methotrexate and Mycophenolate Mofetil for UVEITIS

Role: collaborator

NCT05304182Not ApplicableUnknown

Clinical Study - ES 900 - 2020-1

Role: collaborator

NCT01939691Phase 4Terminated

Macular Edema Nepafenac vs. Difluprednate Uveitis Trial

Role: collaborator

NCT00997035Phase 3Completed

The Mycotic Ulcer Treatment Trial II: A Randomized Trial Comparing Oral Voriconazole vs Placebo

Role: collaborator

NCT01664819Not ApplicableCompleted

Antioxidants for Prevention of Cataracts Follow-up Study

Role: collaborator

NCT00557362Phase 1Completed

Therapeutic Exploratory Study of Comparing Natamycin and Voriconazole to Treat Fungal Corneal Ulcer

Role: collaborator

NCT00324168Phase 4Completed

Steroids for Corneal Ulcers Trial

Role: collaborator

NCT00996736Phase 3Completed

Mycotic Ulcer Treatment Trial I

Role: collaborator

NCT01232920Phase 3Completed

First-line Antimetabolites as Steroid-sparing Treatment Uveitis Pilot Trial

Role: collaborator

All 12 trials loaded